Elan Corporation, plc (ELN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (4285)	4/15/2003 7:19:26 AM
From: Icebrg	Read Replies (1) of 10345

Zonegran Looking in Dainippon's annual report for 2002 it turns out that the drug is also in phase II clinical trials for the treatment of Parkinsons. Erik From the annual report. Zonisamide is an antiepileptic agent developed by Dainippon Pharmaceutical that has been marketed in Japan under the brand name EXCEGRAN- since 1989. At the Neurology Department of the University of Tokyo Hospital, when epilepsy patients with Parkinson's symptoms were given zonisamide, their Parkinson's symptoms improved significantly. These findings attracted a great deal of attention when they were reported at the Annual Meeting of the Japanese Society of Neurology held in May 2001. Parkinson's disease is currently treated with L-dopa, which becomes less effective as the disease progresses. However, zonisamide produces a beneficial effect through a completely different mechanism of action, and there are high expectations for its clinical efficacy. Dainippon Pharmaceutical is currently conducting Phase II trials for an additional indication for zonisamide as a treatment for Parkinson's disease. dainippon-pharm.co.jp

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next